Streetbeat News

Earnings

NVCR

Novocure announced that an exploratory subgroup analysis of the Phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial has been selected for presentation at the European Society on Gynecological Oncology 2024 Congress. The analysis found that PLD-naïve patients receiving TTFields therapy and paclitaxel had a median overall survival of 16.0 months, compared to 11.7 months for those treated with paclitaxel alone.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:16 am

SILV

SilverCrest Metals (AMEX:SILV) reported Q4 earnings of $0.24 per share, surpassing the $0.10 estimate, a 500% increase from last year. Sales reached $61.32M, beating the $44.09M estimate, up 50.33% from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:15 am

VTYX

Ventyx Biosciences announced updates on its clinical pipeline, including positive Phase 1 results for VTX3232, topline Phase 2 data for VTX2735, and supportive early Phase 2 data for VTX002. The company plans to initiate Phase 2a trials for VTX3232 in Parkinson's disease and obesity by H2 2024, evaluate VTX2735 in cardiovascular diseases, and seek partnerships for VTX002's Phase 3 trial in ulcerative colitis. Ventyx also expects its current funds to last into at least H2 2026 due to pipeline reprioritization and recent financing.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:11 am

LEGN

Legend Biotech (NASDAQ:LEGN) reported Q4 earnings with losses of $(0.40) per share, beating the $(0.83) estimate by 51.81%. However, their sales of $79.46M missed the $86.35M estimate by 7.97%. Year-over-year, this represents a 2.44% decrease in losses and a 187.57% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:03 am

EXK

Endeavour Silver reported its Q4 production results, with silver production at 1,406,423 ounces and gold production at 9,608 ounces. The company's performance in silver and gold production is a key indicator of its operational success.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:55 am

EXK

Endeavour Silver (NYSE:EXK) reported Q4 adjusted EPS of $0.02, meeting analyst estimates, with sales of $50.50M surpassing the $49.47M forecast. This represents a 50% decrease in EPS and a 38.41% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:52 am

UEC

Uranium Energy (AMEX:UEC) reported a significant decrease in both earnings and sales for Q2, with earnings per share dropping from $0.03 to $0.01 YoY and sales plummeting from $47.93M to $116.00K YoY.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:46 am

KALV

KalVista Pharma (NASDAQ:KALV) reported a Q3 EPS loss of $(0.84), missing the consensus estimate of $(0.77) by 9.09%. This represents a 12% increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:42 am

FTRE

Fortrea has projected its 2024 sales to be in the range of $3.14B-$3.205B, slightly below the consensus estimate of $3.20B. The company also forecasts its adjusted EBITDA to be between $280M-$320M.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:38 am

FTRE

Fortrea Holdings (NASDAQ:FTRE) reported Q4 adjusted EPS of $0.19, missing the $0.24 estimate, and sales of $775.40M, slightly below the $776.06M estimate. This represents a significant decrease in earnings compared to last year but a slight increase in sales.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:36 am